Anzuini A, Rosanio S, Legrand V, Tocchi M, Coppi R, Bonnier H, Sheiban I, Kulbertus H E, Chierchia S L
Department of Cardiology, San Raffaele Hospital, Milan, Italy.
J Am Coll Cardiol. 1998 Feb;31(2):281-8. doi: 10.1016/s0735-1097(97)00490-7.
This study reports the first multicenter experience with the Wiktor coil stent for treatment of chronic total coronary artery occlusions (CTOs).
Percutaneous transluminal coronary angioplasty (PTCA) of CTO is associated with very high restenosis and reocclusion rates. Coronary stenting has been proposed as a means of improving outcome. However, the Wiktor device for CTOs has never been tested in a large patient sample.
From January 1993 to December 1996, 89 patients with 91 CTOs underwent Wiktor stent implantation after successful PTCA. The post-stenting regimen consisted of warfarin (Coumadin) plus aspirin in the initial 49 patients (55%) and aspirin plus ticlopidine in 40 patients (45%).
Stenting was successful in 87 patients (98%). At 1 month, 6% of patients had subacute stent thrombosis, 3% had a major bleeding event, and 1% had access-site complications. Subacute stent thrombosis showed univariate association with warfarin therapy (p = 0.009). Angiographic follow-up was obtained in 76 (93%) of 82 eligible patients. The restenosis rate was 32%, including 4% reocclusions. By multiple logistic regression analysis, restenosis was independently associated with multiple stents (adjusted odds ratio [OR] 27.67, 95% confidence interval [CI] 4.25 to 79.95, p = 0.0008) and increasing values of occlusion length (adjusted OR 1.23, 95% CI 1.09 to 1.39, p = 0.001). Freedom from death, myocardial infarction or stented vessel revascularization was 87% and 72% at 1 and 3 years, respectively.
Short- and long-term clinical and angiographic outcomes are favorable in patients undergoing Wiktor stent implantation in CTO. Further technical improvement is needed to reduce the restenosis rate in patients with long lesions and multiple stents.
本研究报告了使用维克托(Wiktor)线圈支架治疗慢性冠状动脉完全闭塞(CTO)的首个多中心经验。
CTO的经皮腔内冠状动脉成形术(PTCA)与非常高的再狭窄和再闭塞率相关。冠状动脉支架置入术已被提议作为改善预后的一种方法。然而,用于CTO的维克托装置从未在大量患者样本中进行过测试。
从1993年1月至1996年12月,91例CTO患者中的89例在成功进行PTCA后接受了维克托支架植入。最初的49例患者(55%)术后治疗方案为华法林(香豆素)加阿司匹林,40例患者(45%)为阿司匹林加噻氯匹定。
87例患者(98%)支架置入成功。1个月时,6%的患者发生亚急性支架血栓形成,3%发生大出血事件,1%发生穿刺部位并发症。亚急性支架血栓形成与华法林治疗呈单因素关联(p = 0.009)。82例符合条件的患者中有76例(93%)接受了血管造影随访。再狭窄率为32%,包括4%的再闭塞。通过多因素逻辑回归分析,再狭窄与多个支架独立相关(调整后的优势比[OR]为27.67,95%置信区间[CI]为4.25至79.95,p = 0.0008),且闭塞长度增加也相关(调整后的OR为1.23,95%CI为1.09至1.39,p = 0.001)。术后1年和3年无死亡、心肌梗死或支架血管再血管化的生存率分别为87%和72%。
接受维克托支架植入治疗CTO的患者短期和长期的临床及血管造影结果良好。需要进一步的技术改进以降低长病变和多个支架患者的再狭窄率。